BACKGROUND Acute kidney injury complicating high-dose methotrexate (HDMTX) therapy increases the risk for severe mucositis, myelosuppression, and death. It is unclear whether high-dose leucovorin and supportive therapy without the use of glucarpidase can reduce toxicity from HDMTX. STUDY DESIGN The charts of all patients at Memorial Sloan Kettering Cancer Center whose methotrexate (MTX) drug levels at 48 or 72 hours after administration were 10 times or more the toxic level were reviewed between January 2000 and December 2011. RESULTS Eighty-eight patients (median age 51 years, range 9-90 years) who received 100 courses of HDMTX were identified. Serum creatinine increased by 2-fold from baseline (median, range 1-to 10-fold), but all patients recovered kidney function. Serum levels of MTX were 69 lmol/L (median, range 2.2-400), 6.9 lmol/L (1.3-64), and 2.0 lmol/L (0.05-26) at 24, 48, and 72 hours, respectively, after administration. A statistically significant correlation existed between MTX levels at 48, 72, 96, and 120 hours after administration but not between 24 and 72 hours or subsequent time points. High-dose leucovorin was given in 81% of courses in accordance with institutional protocols in most cases. Myelosuppression was present in 42%; grade III or higher neutropenia in 29%, and thrombocytopenia in 25%. Infectious complications, oral mucositis, and diarrhea occurred in 21%, 17%, and 6% of patients, respectively. Five deaths occurred, none directly attributed to complications from MTX administration. Seven additional patients received glucarpidase at the discretion of a treating physician during the study period, and results are reported separately. CONCLUSION Patients who had 100 episodes of HDMTX-associated acute kidney injury were treated with a strategy that only included usual supportive measures and high-dose leucovorin. No deaths were directly attributed to complications related to HDMTX. Glucarpidase, an expensive drug, may not be necessary for a significant number of patients. KEY WORDS acute kidney injury, high-dose methotrexate, kidney toxicity, glucarpidase, leucovorin. (Pharmacotherapy 2018;38(7):714-724)
High-dose methotrexate (HDMTX) with leucovorin rescue is a component of systemic therapy for osteosarcoma, lymphoma, and leukemia. 1 Administration of HDMTX is associated with the risk of acute kidney injury (AKI), leading to delayed clearance of methotrexate (MTX). Prolonged exposure to elevated MTX levels creates risk for severe mucositis, hematopoietic suppression, and death. Treatment of HDMTX-associated renal dysfunction and delayed MTX excretion is a medical emergency.
Several interventions have been used to treat this life-threatening complication including high-dose leucovorin (HDLV), glucarpidase, and thymidine. Because of the concern that HDLV alone cannot prevent tissue toxicity, 2 glucarpidase (an enzyme that converts MTX into inactive metabolites) was introduced as an agent to prevent or ameliorate MTX toxicity in patients with AKI and delayed MTX clearance. 3 A report of a large series of patients treated with glucarpidase advocated that glucarpidase use should be a standard approach for the management of HDMTX-associated renal dysfunction and delayed MTX excretion. [4] [5] [6] A small series of patients treated successfully with HDLV without glucarpidase was previously reported. 7 More recent experience with the management of HDMTX-associated renal dysfunction and delayed MTX excretion in a larger group of patients treated in a similar fashion are reviewed and reported in this article. The results were also compared with other studies that used glucarpidase. 5, [8] [9] [10] [11] [12] The relationship between the degree of AKI and serial MTX levels, the lack of correlation between MTX levels at 24 hours and subsequent time points, and the influence of additional cytotoxic chemotherapy in the development of severe (grade III or higher) myelosuppression are also analyzed in this article.
Methods
To help identify patients at high risk for developing severe MTX toxicity, various cutoff points were established. 1 At Memorial Sloan Kettering Cancer Center (MSKCC), patients with serum MTX levels 10 lmol/L or higher at 24 hours, 1 lmol/L or higher at 48 hours, and 0.1 lmol/L or higher at 72 hours are considered to be at high risk of impending toxicity. The institution's database was reviewed, and all patients treated between January 2000 and December 2011 who had delayed MTX clearance with MTX levels 10 times or higher of toxic levels at 48 or 72 hours (10 lmol/L or higher at 48 hrs and/or 1 lmol/L or higher at 72 hrs) were considered for inclusion. Because some patients received more than one course of HDMTX, each course of HDMTX was considered as an individual patient for statistical analysis and tabulation in the results.
A retrospective chart analysis at MSKCC was performed after approval by the institutional review board. Patient discharge summaries were used to review the cases and extract data related to myelosuppression, infectious complications, incidence of gastrointestinal toxicity, and mortality. Analysis of laboratory data included serial evaluation of serum creatinine (S cr ) and MTX levels as well as hematologic parameters. MTX was measured in serum using a dihydrofolate reductase inhibition assay. For the purpose of this study, HDLV was defined as 0.4 g/day or more given intravenously. Treatment-related toxicities were graded according to the National Cancer Institute Terminology Criteria for Adverse Events v.4.0.
Results
A total of 88 patients received 100 courses of HDMTX and were treated with the usual supportive measures of hydration and HDLV as the sole mode of therapy. In addition, between January 2000 and December 2011, seven patients who also received glucarpidase are analyzed separately.
The study included children and adults. Median age was 51 years old with a range of 9-90 years (Table 1) . A total of 75% of the patients were 19 years or older. The underlying malignancy included osteosarcoma in 36 courses, central nervous system lymphoma (CNSL) in 30, non-Hodgkin lymphoma in 21, and other malignancies in 13. Baseline S cr was defined as the closest creatinine level to the time of HDMTX administration and ranged between 0.2 and 1.8 mg/dl. Eight patients had underlying abnormal kidney function before administration of HDMTX. The median dose of MTX was 3.5 g/m 2 with a range from 1.0-13 g/m². Sixty-four courses included MTX as a single agent, and 36 of the courses included additional cytotoxic chemotherapy within 2 weeks before or at the time of HDMTX. The chemotherapy agents used in these 36 courses included procarbazine, cyclophosphamide, cytarabine, and doxorubicin, given either as a single agent or in combination. Four patients had received a prior dose of MTX 2 weeks or less before the present course of HDMTX, and one received pegylated asparaginase. A total of 81% of the courses included HDLV, with a median dose of 1 g/day (range 0.4-2.3 g/day) intravenously. In 83% of the courses, HDLV was administered within the first 48 hours. Figure 1 shows the changes in S cr levels following HDMTX. Because of the wide range of baseline S cr levels associated with different ages, weight, sex, and race, the severity of renal dysfunction was expressed as the percentage or fold change from baseline creatinine levels. The S cr increased from a median baseline of 0.85 mg/dl (range 0.2-1.8 mg/dl) to a median peak level of 1.8 (range 0.7-8.1 mg/dl) with 25% of courses having a peak S cr of 2.7 mg/dl or higher. The S cr level increased by a median of 2-fold (range 1-to 10-fold) with 25% of courses having an increase of 3-fold or more than the baseline level. In 27% of courses the increase in S cr was less than 1.5 of baseline, with 8 of these 27 courses having an abnormal creatinine before HDMTX administration. An inverse relationship was observed between the dose of MTX and either the peak S cr or the fold change in creatinine levels. Paradoxically, lower doses tended to produce more nephrotoxicity ( Figure 2 ). The duration of renal dysfunction, as assessed by the number of days that the creatinine levels remained equal or above 1.5 times baseline, is shown in Figure 3 . From those patients who had an increase in creatinine level 1.5 times or higher than baseline, the levels remained above this value for a median time of 11 days, but all patients eventually recovered renal function. One patient required transient hemodialysis. Figure 4 shows the MTX levels during the first 5 days. The median MTX levels at 24, 48, and 72 hours after administration of HDMTX was 69 (range 2.2-400) lmol/L, 6.9 (1.3-64) lmol/L, and 2.0 (0.05-26) lmol/L, respectively. Overall, 25% of courses had MTX levels of 100 lmol/L, 17 lmol/L, and 5 lmol/L or higher at 24, 48, and 72 hours, respectively. Levels of MTX remained above 0.1 lmol/L for a median of 9 days (Figure 4) . No relationship was found between the MTX dose and MTX levels at 24 hours (p=0.96), but there was an inverse correlation at 48 and 72 hours (p=0.04 and p=0.03, respectively). A high correlation was observed between the degree of AKI, as reflected by the peak S cr levels or the fold change and the MTX levels at 48 and 72 hours ( Figure 5 ), but not between changes in renal function and MTX levels at 24 hours. A high correlation was found between the MTX levels at 24 and 48 hours, and between 48 and 72, 96, and 120 hours, but not between 24 and 72, 96, or 120 hours ( Figure 6 ).
In six patients, neutropenia or thrombocytopenia was already present before HDMTX administration, and these patients were not included in the analysis. Grade III or higher neutropenia (absolute neutrophil count lower than 1000/ll) developed in 29% of the courses; grade III or higher thrombocytopenia (platelet count lower than 50,000/ll) developed in 25% of the courses. Thus evidence of myelosuppression was present in 42% of the courses ( Table 1 ). The duration of neutropenia and thrombocytopenia is shown in Figure 7 . Grade III or higher neutropenia or thrombocytopenia occurred in 18 of 36 (50%) courses that included additional cytotoxic chemotherapy but only in 24 of 64 (38%) courses of MTX alone. The influence of additional cytotoxic chemotherapy on myelosuppression can be further appreciated by the fact that of 42 courses associated with neutropenia or thrombocytopenia, 18 (43%) had received other chemotherapy while of 58 courses not associated with myelosuppression, only 18 (31%) had received other chemotherapy (Table 1) . Furthermore, the incidence of myelosuppression was affected by the type of concomitant chemotherapy used: 51% with procarbazine versus 85% when cyclophosphamide, cytarabine, or doxorubicin was used alone or in combination.
A total of 21% of the courses had infectious complications: 11 instances of catheter-related bloodstream infection, 1 of which included concomitant cellulitis at the site of insertion of a central catheter; 3 episodes of neutropenic fever; bleed and urinary obstruction with postmortem examination revealing widely disseminated lymphoma. Care was withdrawn in two patients with CNSL and one with brain metastases associated with breast cancer due to progressive deterioration of mental status and seizures. One patient with chronic lymphocytic leukemia admitted with fever and pulmonary infiltrates developed adult respiratory distress syndrome leading to withdrawal of care.
Between January 2000 and December 2011, seven patients were treated with glucarpidase at the discretion of a treating physician (results shown in Table 2 ). Two patients required hemodialysis. Patient 2 was anuric with multisystem organ failure (which was present before administration of HDMTX), and hemodialysis was started when the S cr was only 1.5 mg/dl because of fluid overload and respiratory failure. The patient died from complications related to sepsis and multiorgan failure. In patient 6, hemodialysis was started because of worsening renal function. In five patients (patients 1, 3, 4, 5, and 7), glucarpidase was administered at MTX levels that were within the range and the time frame observed in the group of patients who were treated with HDLV and supportive measures alone. Patient 1 received glucarpidase 32 hours after HDMTX because the initial 24 hours MTX level was erroneously reported as 500 lmol/L at 24 hours instead of the correct level of 50 lmol/L. Grade III or higher neutropenia developed in three patients and thrombocytopenia in two patients. In patient 2, pancytopenia was present before MTX administration. 
Discussion
In this study, 100 episodes of HDMTX-associated renal dysfunction were treated with a strategy that included HDLV and aggressive hydration with alkaline solutions, without the use of glucarpidase. No mortality was directly attributed to MTX toxicity. All patients successfully cleared MTX to a level that allowed safe discontinuation of leucovorin. All patients recovered kidney function. This study compares well with recent reports that used glucarpidase to treat similar patients. 5, [8] [9] [10] [11] [12] The demographic characteristics of the patients studied, including range of MTX dose, range of MTX levels, and degree of AKI, were similar to that in recent publications (Table 3) .
Regarding nephrotoxicity, a significant and inverse relationship was found between lower MTX dose and the severity of HDMTX-induced AKI. This could have been related to the fact that 50% of the patients were 51 years or older, and sicker and older patients tend to receive lower doses. Elderly individuals may be more prone to AKI from HDMTX as reflected by an incidence of grade III or higher nephrotoxicity of 4-5% in elderly patients with CNSL versus 0.6% in young patients with osteosarcoma. [13] [14] [15] The MTX in the renal collecting system is likely unaffected by the administration of glucarpidase because it only acts on extracellular MTX. 16 This fact was reflected in another study where a similar rate of renal recovery was observed, as in other reports. 5, [10] [11] [12] Although in three other studies the median MTX levels at 48-96 hours were higher, the range of MTX levels was similar to the levels in this study. 5, 11, 12 No correlation between the MTX levels at 24 hours and subsequent evidence of delayed MTX clearance was observed, as reflected by the MTX levels at 72, 96, and 120 hours ( Figure 6 ). Similarly, no correlation was found between MTX levels at 24 hours and increases in creatinine levels, although the MTX levels at 48 and 72 hours correlated with the severity of AKI (Figure 5 ). These findings suggest that MTX levels obtained during the first 24 hours after MTX administration are not predictive of subsequent high MTX levels and should not be used as the basis for glucarpidase administration. Furthermore, high MTX levels during the first 24 hours before HDLV were reported to produce minimal toxicity. 1 Of note, in the reports where glucarpidase was used, this agent was often administered during the first 24 hours. Even after the first dose, additional doses of glucarpidase were given to some patients, although the MTX levels fell well within the range reported here.
The incidence of myelosuppression, mucositis, diarrhea, and infections was comparable with the studies where glucarpidase was used. Furthermore, 36% of the courses received concomitant cytotoxic chemotherapy, which by itself can be responsible for or exacerbate myelosuppression and mucositis. In the studies that reported statistics regarding the use of additional chemotherapy, the incidence of infection, grade III or higher mucositis, and myelosuppression were similar or higher than in the present study. Despite the older age of the patients, no deaths were directly attributed to MTX toxicity, although even when glucarpidase is used, death rates of up to 23% were reported in the literature. 5, 9, 10 The timely administration of adequate doses of HDLV is essential, no matter what other modalities are used. In the published experience with glucarpidase, elderly patients, patients who received concomitant cytotoxic chemotherapy, and those who received delayed and/or inadequate dosing of HDLV had higher rates of systemic toxicity and death (Table 3 ). In the study cited earlier, 5 the correlation between inadequate dosing of HDLV and death was one, and for this reason, HDLV dosing was omitted from the multivariable analysis assessing the factors predicting success for the use of glucarpidase. Administration of glucarpidase results in a rapid decrease in plasma MTX levels, but no data are available on its effect on the intracellular compartment. Administration of glucarpidase requires interruption of HDLV administration, increasing the risk of MTX toxicity during that interruption, and it makes measurement of plasma MTX levels unreliable, increasing the complexity of management. In addition, glucarpidase is an extremely expensive drug with an estimated cost of~$108,000 per dose in a 70-kg individual. 3 
Conclusion
These results suggest that glucarpidase use in the setting of HDMTX-associated renal failure and delayed MTX excretion should be limited for patients with MTX levels above the range observed in this study or for patients who have oliguric renal failure, where the strategy of HDLV and aggressive alkaline hydration cannot succeed. For patients with nonoliguric renal dysfunction and with MTX levels similar to those in this study, avoidance of glucarpidase appears to be safe in a significant number of patients as long as HDLV is initiated within the first 48 hours and according to published guidelines. 1, 17 Additional seven patients who received glucarpidase in the current study are described in the text and in Table 2 .
